Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database

  • Keiko HosohataEmail author
  • Ayaka Inada
  • Saki Oyama
  • Iku Niinomi
  • Tomohito Wakabayashi
  • Kazunori Iwanaga
Original Research Article


Background and Objective

Adverse cutaneous drug reactions associated with antiepileptic drugs (AEDs) are a serious problem in the clinical setting. New-generation AEDs have been reported to be better tolerated than old-generation forms; however, information about the risks of adverse cutaneous drug reactions to new-generation AEDs is limited.


The purpose of this study was to clarify the association of AEDs with adverse cutaneous drug reactions using a spontaneous reporting database.


We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between April 2004 and January 2017 were analyzed. Based on reports of all adverse events, we obtained 4805 reports of adverse cutaneous drug reactions associated with AEDs, and calculated the reporting odds ratio (ROR) and 95% confidence interval (CI) for drug rash, Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).


Individual AEDs had variable signals for drug rash, SJS, and TEN. The strongest signals were detected for drug rash caused by lamotrigine (ROR 9.18, 95% CI 8.65–9.74), SJS caused by zonisamide (ROR 9.85, 95% CI 8.23–11.78), and TEN caused by phenobarbital (ROR 14.08, 95% CI 11.28–17.57).


There are clear differences in the risk of cutaneous reactions among AEDs, and further studies are needed to confirm these findings.


Author Contributions

KH, AI, and SO conceived and designed the study; KH, AI, SO, IN, TW, and KI analyzed the data and drafted the manuscript. All authors have read and approved the final manuscript submitted for publication.

Compliance with Ethical Standards


Keiko Hosohata received research support from the Science Research Promotion Fund (Grant no. 42).

Conflict of interest

Keiko Hosohata, Ayaka Inada, Saki Oyama, Iku Niinomi, Tomohito Wakabayashi and Kazunori Iwanaga report no conflicts of interest related to this work.

Supplementary material

40261_2019_754_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 14 kb)


  1. 1.
    Van de Vel A, Cuppens K, Bonroy B, Milosevic M, Jansen K, Van Huffel S, et al. Non-eeg seizure-detection systems and potential sudep prevention: state of the art. Seizure. 2013;22:345–55.CrossRefGoogle Scholar
  2. 2.
    Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77:1005–12.CrossRefGoogle Scholar
  3. 3.
    Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M. Specific adverse effects of antiepileptic drugs–a true-to-life monotherapy study. Epilepsy Behav. 2016;54:150–7.CrossRefGoogle Scholar
  4. 4.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9.CrossRefGoogle Scholar
  5. 5.
    Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72:1223–9.CrossRefGoogle Scholar
  6. 6.
    Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402–8.CrossRefGoogle Scholar
  7. 7.
    Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens–Johnson Syndrome and toxic epidermal necrolysis in europe and israel. J Am Acad Dermatol. 2008;58:25–32.CrossRefGoogle Scholar
  8. 8.
    Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450–9.CrossRefGoogle Scholar
  9. 9.
    Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128:422–8.CrossRefGoogle Scholar
  10. 10.
    Mahe J, de Campaigno EP, Chene AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from Vigibase. Br J Clin Pharmacol. 2018;84(10):2373–83.CrossRefGoogle Scholar
  11. 11.
    Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Therap. 2014;39:307–13.CrossRefGoogle Scholar
  12. 12.
    Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Therap. 2019;44(1):49–53.CrossRefGoogle Scholar
  13. 13.
    Gosho M. Risk of hypoglycemia after concomitant use of antidiabetic, antihypertensive, and antihyperlipidemic medications: a database study. J Clin Pharmacol. 2018;58(10):1324–31.CrossRefGoogle Scholar
  14. 14.
    Hosohata K, Matsuoka E, Inada A, Oyama S, Niinomi I, Mori Y, et al. Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients. J Int Med Res. 2018;46(11):4617–23.CrossRefGoogle Scholar
  15. 15.
    Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, et al. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Therap Clin Risk Manag. 2018;14:1599–604.CrossRefGoogle Scholar
  16. 16.
    Kose E. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database. J Clin Pharm Therap. 2018;43:543–9.CrossRefGoogle Scholar
  17. 17.
    Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry Clin Neurosci. 2019;73(1):27–33.Google Scholar
  18. 18.
    Bate A, Evans SJ. Quantitative signal detection using spontaneous adr reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.CrossRefGoogle Scholar
  19. 19.
    Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23:195–207.CrossRefGoogle Scholar
  20. 20.
    Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627–45.CrossRefGoogle Scholar
  21. 21.
    Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R. Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs. Drugs Aging. 2017;34:479–87.CrossRefGoogle Scholar
  22. 22.
    Mohd-Tahir NA, Li SC. Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children. Epilepsy Res. 2018;139:113–22.CrossRefGoogle Scholar
  23. 23.
    Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: Influence by gender, age, and learning disability. Epilepsia. 2007;48:1360–5.CrossRefGoogle Scholar
  24. 24.
    Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–15.CrossRefGoogle Scholar
  25. 25.
    Zeng QY, Fan TT, Zhu P, He RQ, Bao YX, Zheng RY, et al. Comparative long-term effectiveness of a monotherapy with five antiepileptic drugs for focal epilepsy in adult patients: a prospective cohort study. PLoS One. 2015;10:e0131566.CrossRefGoogle Scholar
  26. 26.
    Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson Syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.CrossRefGoogle Scholar
  27. 27.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The euroscar-study. J Investig Dermatol. 2008;128:35–44.CrossRefGoogle Scholar
  28. 28.
    Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens–Johnson Syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64:1134–8.CrossRefGoogle Scholar
  29. 29.
    Lee HJ, Son JM, Mun J, Kim DW. Safety and efficacy of zonisamide in patients with epilepsy: a post-marketing surveillance study. J Epilepsy Res. 2015;5:89–95.CrossRefGoogle Scholar
  30. 30.
    Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21:489–501.CrossRefGoogle Scholar
  31. 31.
    Wang XQ, Shi XB, Au R, Chen FS, Wang F, Lang SY. Influence of chemical structure on skin reactions induced by antiepileptic drugs—the role of the aromatic ring. Epilepsy Res. 2011;94:213–7.CrossRefGoogle Scholar
  32. 32.
    Lu W, Uetrecht JP. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos. 2007;35:1050–6.CrossRefGoogle Scholar
  33. 33.
    Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific t cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393–403.CrossRefGoogle Scholar
  34. 34.
    Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol. 2009;22:144–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Education and Research Center for Clinical PharmacyOsaka University of Pharmaceutical SciencesTakatsukiJapan

Personalised recommendations